Delisting risk
Cuprina Class A (CUPR)
Develops prescription live-larva products for chronic-wound debridement.
$2.75
Pre-market−0.09 (−3.17%)
At close$2.84(−2.07%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions4 holders · as of Mar 31, 2026 | 0.41% | 11.1K ADS | |
| Otherremainder | 99.59% | 2.67M ADS |
2.68M ADS as of Aug 28, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's May 2025 annual report; nothing newer is on file here.
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Institutions13F, as of Mar 31, 2026
4 holders · 88.4K shares · 2 new positions · 2 increased · 2 reduced · 1 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Citadel Advisors LLC | 37.3K | 1.39% | +37.3Knew | May 15, 2026 |
| XTX Topco Ltd | 35.5K | 1.32% | +35.5Knew | May 15, 2026 |
| Prospect Financial Group LLC | 15.3K | 0.57% | −9.6K | May 6, 2026 |
| UBS Group AG | 363 | 0.01% | −11.6K | May 5, 2026 |
Ownership statements13D/G · 5% or more, as filed
No 13D/G filer at 5% or more on record.
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.
